The Prevalence and Economic Impact of Low-Enrolling Clinical Studies at an Academic Medical Center

Abstract

Purpose The authors sought to assess the prevalence and associated economic impact of low-enrolling clinical studies at a single academic medical center. Method The authors examined all clinical studies receiving institutional review board (IRB) review between FY2006-FY2009 at Oregon Health & Science University (OHSU) for recruitment performance and analyzed them by type of IRB review (full-board, exempt, expedited), funding mechanism, and academic unit. A low-enrolling study included those with zero or one participant at the time of study termination. The authors calculated the costs associated with IRB review, financial set-up, contract negotiation, and department study start-up activities and the total economic impact on OHSU of low-enrolling studies for FY2009. Results A total of 837 clinical studies were terminated during the study period, 260 (31.1%) of which were low-enrolling. A greater proportion of low-enrolling studies were government-funded than industry-funded (P=.006). The authors found significant differences among the various academic units with respect to percentages of low-enrolling studies (from 10% to 67%). The uncompensated economic impact of low-enrolling studies was conservatively estimated to be nearly $1 million for FY2009. Conclusions A substantial proportion of clinical studies incurred high institutional and departmental expense but resulted in little scientific benefit. While a certain percentage of low-enrolling studies can be expected in any research organization, the overall number of such studies must be managed to reduce the aggregate costs of conducting research and to maximize research opportunities. Effective, proactive interventions are needed to address the prevalence and impact of low enrollment.

Permission to Contact (PTC)—A Strategy to Enhance Patient Engagement in Translational Research

“…In practice, these steps are often merged; referral and preliminary interview may be conducted at the same time by a physician, and the consent interview step subsequently completed by the study, or all three steps may be accomplished by a physician. In addition, consent can be obtained as part of either pre-and post-procedure protocols, 1 University of British Columbia, Office of Biobank Education and Research, Vancouver, British Columbia, Canada. 2 Tumour Tissue Repository, British Columbia (BC) Cancer Agency, Victoria, British Columbia, Canada.…”

“…1 For example, less than 5% of patients are enrolled into clinical cancer trials. 2 One of the barriers to enrollment is the recruitment process and access to suitable and interested patients/participants.…”

Predicting Low Accrual in the National Cancer Institute’s Cooperative Group Clinical Trials

“…Clinical trials that do not achieve sufficient accrual are frequently unable to inform clinical practice or benefit patients (1-3). Moreover, low-accruing clinical trials often represent a waste of scarce human and economic resources (4).…”

Highly Effective Cystic Fibrosis Clinical Research Teams: Critical Success Factors

“…Sub-optimal conduct of clinical trials in academic medical centers both raises the costs to institutions and sponsors and delays the availability of new therapies. 1 The slow development of protocols, redundant scientific and ethical reviews, and protocol requirements that hinder enrollment contribute to the inferior conduct of clinical trials in academic centers. [2][3][4] In 2006, the Clinical and Translational Science Award (CTSA) program of the National Institutes of Health (NIH) was developed to support a national consortium of biomedical research institutions to accelerate progress in clinical research.…”